REG - Craven House Capital - Investee Companies' Update

Craven House CapitalAnnouncement

28/11/2023 16:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231128:nRSb9544Ua&default-theme=true

RNS Number : 9544U  Craven House Capital PLC  28 November 2023

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF REGULATION
(EU) 596/2014 AS IT FORMS PART OF DOMESTIC LAW IN THE UNITED KINGDOM BY VIRTUE
OF THE EU (WITHDRAWAL) ACT 2018.

Craven House Capital plc

("Craven House" or the "Company")

Investee Companies' Update

Craven House Capital plc ("Craven House" or the "Company"), the AIM quoted
investment company, provides the following update regarding its investee
companies following a review completed today of the Company's investment
portfolio in preparation of the publication of its Annual Report and Accounts
for the year to May 2023.

Garimon Limited - 29.9% shareholding

As at end May 2023 Garimon's assets comprised ownership of the domain
www.magazinos.com, a platform for digital magazine distribution, with over
10,000 magazines freely available for readers. Limited progress was
demonstrated in relation to development and growth of this domain during the
year. Despite the potential future value of this investment, the fair value
has been impaired to zero due to the current absence of tangible arm's length
or market-based valuation metrics.

Stormfjord Limited - 25.5% shareholding

As previously announced the www.onebas.com domain was transferred out of
Garimon during the period and into a new entity, Stormfjord Ltd. Stormfjord
subsequently raised $520,000 of arms-length financing, which valued the domain
at $5,000,000. The proceeds of the financing were used to upgrade the
functionality and capacity of the websites as well as launch a PR /
advertising campaign across key target markets.

A subsequent round of fundraising was completed in March 2023, raising
$100,000 (announced on March 3, 2023) at a valuation of $28,000,000. Craven
did not participate in either fundraising. Despite the potential future value
of this investment, the fair value has been impaired to zero due to the
current absence of tangible arm's length or market-based valuation metrics.

Bio Vitos Medical Limited - 24.5% shareholding

Bio Vitos has two principal assets;

In the prior year Bio Vitos acquired the licence to market a patented heart
drug 'Succifer' (also marketed as 'Inofer'), from Double Bond Pharmaceutical
AB. The drug has been demonstrated to improve iron uptake in patients with
chronic heart conditions

 

As publicly disclosed, after the end of the period BioVitos completed its
transaction with Hemcheck Sweden AB (a Swedish medical technology company,
listed on the Stockholm Stock Exchange) whereby BioVitos has completed an RTO
into Hemcheck in a transaction which will value Succifer at $5,000,000. As a
result BioVitos will be issued 259,654,000 shares in Hemcheck.

Craven House remains a 24.5% shareholder in BioVitos and will receive a
pro-rata distribution of Hemcheck shares shortly after they are awarded to
BioVitos (anticipated in December 2023). As a result Craven received
c.63,615,230 shares in Hemcheck which have a current market value of c. 12
million Swedish Kroner / $1.136m US Dollars, which the board believes
accurately reflects the current fair value for this investment.

The dietary / Omega-3 supplement products owned by BioVitos in the prior
period have now been transferred to a new entity, Rosemonkey Ltd, in which
Craven is a shareholder.

Rosedog Limited - 28.6% shareholder

Rosedog is the owner of TV Zinos (www.tvzinos.com), a website which offers a
number of free-to-view television channels.

As publicly announced on March 3, 2023, Rosedog raised $70,000 on 1st March
2023 at a valuation of $28,000,000. Following completion of the fundraising,
Craven House's holding of 29,900,000 shares represents 28.6% of Rosedog.
Despite the potential future value of this investment, the fair value has been
impaired to zero due to the current absence of tangible arm's length or
market-based valuation metrics.

Honeydog Ltd - 29.9% shareholder

Honey dog the 25% owner of the entity which owns the licence to manufacture
and distribute the chemotherapy drug, SI-053 / 'Temodex' which is used in the
treatment of brain tumours, offering significant increases in survival rates.
Preparation for the finalisation of clinical trials is ongoing. Despite the
potential future value of this investment, the fair value has been impaired to
zero due to the current absence of tangible arm's length or market-based
valuation metrics.

 

For further information please contact:

 Craven House Capital Plc                                                Tel: 0203 286 8130

 Mark Pajak

 www.Cravenhousecapital.com (http://www.cravenhousecapital.com/)

 SI Capital                                                              Tel: 01483 413500

 Broker

 Nick Emerson

 www.sicapital.co.uk (http://www.sicapital.co.uk/)

 SPARK Advisory Partners Limited                                         Tel: 0203 368 3550

 Nominated Adviser

 Matt Davis

 www.Sparkadvisorypartners.com (http://www.sparkadvisorypartners.com/)

 

About Craven House Capital:

The Company's Investing Policy is primarily to invest in or acquire a
portfolio of companies, partnerships, joint ventures, businesses or other
assets participating in the e-Commerce sector.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDBLBDBUGDDGXI